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Background: Neurodevelopmental disorders such as autism and intellectual disability have a sex bias skewed
towards boys; however, systematic assessment of this bias is complicated by the presence of significant genetic
and phenotypic heterogeneity of these disorders.
Methods: To assess the extent and characteristics of sex bias, we analyzed the frequency of comorbid features, the
magnitude of genetic load, and the existence of family history within 32,155 individuals ascertained clinically for
autism or intellectual disability/developmental delay (ID/DD), including a subset of 8,373 individuals carrying rare
copy-number variants (CNVs).
Results: We find that girls were more likely than boys to show comorbid features within both autism
(P = 2.9 × 10−6, OR = 1.34) and ID/DD (P = 7.2 × 10−4, OR = 1.08) cohorts. The frequency of comorbid features in
ID/DD was higher in boys (1q21.1 deletion, 15q11.2q13.1 duplication) or girls (15q13.3 deletion, 16p11.2
deletion) carrying specific CNVs associated with variable expressivity while such differences were the smallest
for syndromic CNVs (Smith-Magenis syndrome, DiGeorge syndrome). The extent of the male sex bias also
varied according to the specific comorbid feature, being most extreme for autism with psychiatric
comorbidities and least extreme for autism comorbid with epilepsy. The sex ratio was also specific to certain
CNVs, from an 8:1 male:female ratio observed among autistic individuals carrying the 22q11.2 duplication to
1.3:1 male:female ratio in those carrying the 16p11.2 deletion. Girls carried a higher burden of large CNVs
compared to boys for autism or ID/DD, and this difference diminished when severe comorbidities were
considered. Affected boys showed a higher frequency of neuropsychiatric family histories such as autism (P =
0.01) or specific learning disability (P = 0.03), while affected girls showed a higher frequency of developmental
family histories such as growth abnormalities (P = 0.02).
Conclusions: The sex bias within neurodevelopmental disorders is influenced by the presence of specific
comorbidities, specific CNVs, mutational burden, and pre-existing family history of neurodevelopmental
phenotypes.Background
Neurodevelopmental disorders such as autism and intel-
lectual disability/developmental delay (ID/DD) are associ-
ated with a sex bias, with the diagnosis skewing towards
boys compared to girls. For example, a male:female ratio
of 2:1 exists among individuals with ID/DD [1, 2] and a 4:1
ratio for individuals with autism diagnoses [3, 4]. Emerging* Correspondence: sxg47@psu.edu
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explanation for the lower number of girls affected with
these disorders. However, systematic assessment of sex
bias in relation to neurodevelopmental disorders has been
complicated by several factors. First, neurodevelopmental
disorders are often associated with extensive phenotypic
heterogeneity. While most studies assign individuals into
one broader-yet-distinct disease nosology, such as autism
or ID/DD disorders, a range of developmental and behav-
ioral phenotypes are comorbid to a large extent in these
cohorts [7]. For example, a comorbidity of intellectual dis-
ability has been observed in as high as 70 % of individuals
diagnosed with autism [4, 8, 9]. Similarly, a comorbidity ofis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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uals with autism [10, 11]. These high rates of comorbidity
were not limited to autism alone. In fact, 6 % to 50 % of
individuals with epilepsy were reported to also have some
psychiatric disorder [12] and 28 % to 40 % of individuals
with intellectual disability were reported to have autistic
features [9, 13].
Second, hundreds of genes and genomic regions have
been identified for each of these neurodevelopmental
disorders from studies of copy number variants (CNVs)
and exome sequencing, suggesting significant genetic
heterogeneity [14–17]. For example, CNVs including
7q11.23 duplication [18–20], 16p11.2 deletion [21–23],
17q12 deletion [24–26], 15q13.3 deletion [27–29],
22q11.2 deletion [30–32], and gene disruptive mutations
in CHD2 [33–35] and SYNGAP1 [34–37] have all been
significantly associated with ID/DD, autism, and schizo-
phrenia phenotypes from independent cohort studies.
Further, these genetic factors can compound to create
severe or variable presentations [38, 39]. In fact, the
CNV load as assessed by the frequency and size of rare
CNVs in an individual has been correlated with a range
of distinct disorders including dyslexia, bipolar disorder,
schizophrenia, autism, and ID/DD [40–42].
Third, there has been a pervasive existence of family
history of neuropsychiatric phenotypes reported within
these disorders which may explain why affected individ-
uals present with certain features over others [43–47]. In
one recent example, phenotypic manifestations in indi-
viduals carrying de novo CNVs associated with variable
expressivity correlated with parental phenotypes; parents
with lower IQ scores were more likely to have children
with a diagnosis of ID/DD and parents with higher social
responsive scores (SRS) were more likely to have chil-
dren with a diagnosis of autism [48, 49]. Other studies
have also reported that parents of children with autism
more frequently manifest autistic, schizophrenic, or bi-
polar features than parents of typically developing chil-
dren [45, 50]. When a family history of other affected
individuals exist, it is known that the sex of the affected
individual will impact recurrence risk and higher risks
associated with male probands, suggesting that girls may
require a higher familial etiologic load to manifest neu-
rodevelopmental phenotypes [51–54].
We hypothesized that these factors influence, to dif-
ferent extents, the sex bias present in neurodevelop-
mental disorders. We therefore assessed sex bias in
relation to the presence of comorbid features, CNV
load, and family history of developmental and behav-
ioral features among 32,155 individuals with autism
and ID/DD features who were referred for genetic
testing by clinicians. Our results support a model where
the genetic liability for manifestation of neurodevelop-
mental phenotypes exists at different thresholds in boysand girls. These thresholds can be altered by the frequency
and type of comorbid features, presence of disease-




We analyzed clinical and CNV data from 54,370 individ-
uals referred by clinicians to Signature Genomic Labora-
tories, LLC, for clinical testing from over 40 referral
sites primarily in the United States and Canada (Fig. 1).
Of these, 32,155 individuals showed features of autism
or ID/DD. In this study, only de-identified phenotypic
(case histories and clinical information) and CNV data
were used (exempt from IRB review) and research con-
formed to the Helsinki Declaration. The phenotypic data
consisted of diagnostic indications, age, and sex informa-
tion reported through requisition forms by geneticists,
pediatricians, and neurologists who have had direct con-
tact with the patient. Patient indications included features
of autism and/or ID/DD with or without comorbidities
(or co-occurring features) such as epilepsy, speech, motor
and language deficits, behavioral and psychiatric issues
including schizophrenia and bipolar disorder, and other
congenital malformations including cardiac defects, renal
and genitourinary abnormalities, and craniofacial and
skeletal features.
We curated a list of more than 75 non-redundant key-
words corresponding to diagnostic terms from physician-
reported clinical indications (Additional file 1: Table S1).
In order to uniformly assess the frequency of phenotypes,
we binned the diagnostic terms into seven broadly defined
categories similar to the US Department of Education dis-
ability categories in special education according to the In-
dividuals with Disabilities Education Act (IDEA) [55]. The
seven phenotypic categories are autism, ID/DD, other
health impairments (OHI), psychiatric disorders, behav-
ioral disorders, speech and language impairments, and
specific learning disabilities (Additional file 1: Table S1).
For example, keywords such as ‘autism’ or ‘PDD’ were
binned into the autism category, while ‘cognitive def-
icit’ or ‘mental retardation’ went into the ID/DD cat-
egory, and ‘epilepsy’, ‘ADHD’, or ‘cardiac’ were binned
into a broader OHI category). The OHI category, as
defined previously [55], consisted of developmental
and behavioral phenotypes that did not fit into any of
the other categories. This category included growth
abnormalities, dysmorphic features, cardiac malforma-
tions, epilepsy, attention deficit disorders, other CNS
malformations, and other congenital malformations.
Frequencies of comorbid features were assessed from
all individuals with autism alone (n = 3,602), ID/DD
alone (n = 26,283), both autism and ID/DD (n = 2,270),
from clinics (n = 32,155), from the subset with rare CNVs
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Fig. 1 Schematic of cohorts derived from the clinical testing population. The schematic shows datasets derived from the Signature Genomics
clinical testing population including the filtering of CNV calls to remove false-positive detection. Note that CNVs were removed if there was a >10 %
overlap with a list of artifact CNV calls (Additional file 1: Table S2). Rare CNVs were derived after removing the CNV calls greater than 0.1 % frequency in
a control cohort (>8/8,329 controls)
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602), and from the subset carrying a CNV associated with
genomic disorders (n = 1,368), and male and female sub-
sets, separately (Fig. 1). Individuals with autism or ID also
manifesting more than one comorbid feature were catego-
rized into ‘multiple features’ or ‘multiple OHI features’ cat-
egories. Individuals with autism and ID/DD were included
in the analysis of both autism and ID/DD cohorts.
We were also able to manually extract family his-
tory of one or more phenotypes from 386 affected in-
dividuals. Frequency of each type of family history
relative to all cases with a family history was then
calculated for boys and girls. We created a matrix by
using the number of individuals with a specific indi-
cation and a specific family history as the numerator
and the number of individuals with that indicationwith any positive family history as the denominator.
Family histories were binned into 12 phenotypic cat-
egories, which can be placed into two broad groups
based on the age-specific prevalence of these pheno-
types (Additional file 1: Figure S1). Family history of
features present at younger ages such as ID/DD, dys-
morphic features, other congenital malformations,
growth abnormalities, and cardiac malformations were
binned into ID/DD and multiple congenital anomalies
(MCA) disorders. Family history of features present in
older children such as epilepsy, other CNS malformations,
autism, psychiatric disorders, attention deficit disorders,
speech and language impairments, and specific learning
disabilities were binned into neuropsychiatric/behavioral
disorders. To reduce overlap of frequently co-occurring
features such as ID/DD, autism, and epilepsy, certain filters
Polyak et al. Genome Medicine  (2015) 7:94 Page 4 of 11were also applied to both clinical indications and family
history information. Then, we separately analyzed com-
monly occurring pairs of comorbid features including aut-
ism with ID/DD and ID/DD with epilepsy.
CNV data
CNVs were identified and analyzed using whole genome
oligonucleotide microarrays (customized SignatureChipOS
v2 and v3 with 135,000 probes from Roche NimbleGen,
Madison, WI, USA and customized SignatureChipOS v1
and v4 with 105,000 probes from Agilent Technologies,
Santa Clara, CA, USA) and validated by fluorescence in situ
hybridization as described previously [30, 56, 57]. CNV calls
were subjected to quality-control filtering to remove false
positive and non-specific detections, technical artifacts, calls
due to reference CNVs, and variants embedded within
complex segmental duplications (Fig. 1). Rare CNVs were
filtered to include only those ranging between 50 kbp and
30 Mbp and occurring at <0.1 % frequency compared to
8,329 controls [30, 56]. Further filtering was applied to in-
clude only those CNVs with <50 % overlap with segmental
duplications and <10 % overlap with a list of CNV artifacts
curated from previous studies (Additional file 1: Table S2).
Due to lack of control data on sex chromosomes, only
autosomal CNVs were considered. After quality control,
8,373 individuals with features of autism and/or ID/DD car-
rying rare CNVs were available for analysis. This group in-
cluded recently published individuals with CNVs mapping
within the 72 chromosomal regions associated with gen-
omic disorders [56]; their phenotypic data were also in-
cluded for this analysis. The genomic disorder CNVs were
classified into those that are mostly de novo in occurrence
and resulting in a typical constellation of clinical features
(syndromes) and those that are often inherited and associ-
ated with various neurodevelopmental phenotypes includ-
ing autism, schizophrenia, ID/DD, and epilepsy (variable
expressivity) as described previously [56]. For replication of
results obtained from the Signature cohort, we also uti-
lized CNV data from individuals with autism from two in-
dependently ascertained cohorts: the Simons Simplex
Collection (1,124 children) [19] and the Childhood Aut-
ism Risks from Genetics and Environment (CHARGE)
study (272 children with autism and 242 typically develop-
ing controls) [42].
CNV burden was calculated as the population frequency
of the largest CNV and plotted as a survivor function [58].
The population frequencies of the largest CNV at a given
size threshold (≥1 Mbp, ≥1.5 Mbp, ≥2 Mbp) were com-
pared with different combinations of comorbid features as-
sociated with autism or ID/DD disorders using Fisher’s
exact test. One-tailed P values were used to determine sig-
nificance for all statistical tests of comparison. A list of all
rare CNV calls analyzed in this study is given in Additional
file 1: Table S3. Rare CNV data used in this study were alsodeposited into dbVar (accession number: nstd113). Com-
prehensive tables including all statistical analyses (one-
tailed and two-tailed P values) and their corresponding
Bonferroni multiple testing corrections are included as
Additional file 1: Tables S4-S8.
Results
We analyzed clinical and CNV data from 54,370 individ-
uals that were referred to Signature Genomic Laborator-
ies for genetic testing by array CGH. Using keyword
searches of physician-reported clinical indications, we
identified 32,155 individuals with features of autism or
ID/DD with or without comorbid features. Figure 1
shows a breakdown of the number of boys and girls with
features of autism (n = 5,872) or ID/DD (n = 28,553),
with 2,270 individuals manifesting both autism and ID/
DD. From this cohort, 1,368 individuals carried rare
CNVs associated with genomic disorders that were
either syndromic or variable in clinical presentation [56],
and 8,373 individuals carried rare CNVs seen in less
than 0.1 % (<8/8,329) of the control population.
Comorbid features in boys and girls with autism or ID/DD
disorders
Overall, comorbid features existed in 51 % (3,004/5,872)
of individuals with autism and 59 % (16,902/28,553) of in-
dividuals with ID/DD (Fig. 2a, b). The total frequency of
all comorbid features was higher among girls compared to
boys within cohorts manifesting autism (P = 2.94 × 10−6,
OR = 1.34, 95 % CI = 1.18-1.52) or ID/DD (P = 7.15 × 10−4,
OR = 1.08, 95 % CI = 1.03-1.14) features (Additional file 1:
Tables S4 and S5). This trend was also observed when a
subset of individuals with rare CNVs (<0.1 % population
frequency) was considered. We also analyzed the frequency
of specific comorbid features binned under the OHI
category including epilepsy, cardiac malformation, growth
abnormalities, dysmorphic features, attention-deficit disor-
ders, other CNS malformation, and other congenital mal-
formation (Additional file 1: Table S1). Among individuals
with any OHI comorbidity, girls with autism (P = 0.01,
OR = 1.64, 95 % CI = 1.07–2.50) or ID/DD (P = 0.009,
OR = 1.14, 95 % CI = 1.02–1.27) were more likely to
show comorbid features of epilepsy compared to boys
(Additional file 1: Figure S2, Tables S6, S7). Among
individuals with ID/DD and any OHI comorbidity,
boys were more likely to show comorbidity of dysmorphic
features (P = 0.004, OR = 1.10, 95 % CI = 1.02–1.18) and
attention deficit disorders (P = 0.0006, OR = 1.95, 95 % CI =
1.29–3.03) compared to girls (Additional file 1: Table S7).
We analyzed comorbidity rates within a subset of
1,368 individuals carrying specific deletions and duplica-
tions associated with genomic disorders and compared
the frequency of comorbid features in boys and girls. Be-
cause we restricted our analysis to sample sizes ≥10, we


















































































































Fig. 2 Comorbidity within autism and ID/DD. The frequency of comorbid features within (a) all cases with autism (n = 5,872), boys (n = 4,588) and
girls (n = 1,284) with autism, and within (b) all individuals with ID/DD (n = 28,553), boys (n = 17,061) and girls (n = 11,492) with ID/DD is shown.
The frequency of comorbid features within (c) girls (F) and boys (M) is shown for a representative set of genomic disorders. Additional file 1:
Table S8 shows data for all CNVs with sample sizes >10. Due to a limited sample size within the genomic disorder cohort, only ID/DD can be
shown. Samples sizes for the CNVs are: 1q21.1 del: M = 30, F = 21; 15q13.3 del: M = 25, F = 20; 16p11.2 del: M = 45, F = 29; 16p12.1 del: M = 20,
F = 9; 16p13.11 del: M = 25, F = 26; 1q21.1 dup: M = 27, F = 20; 15q11.2q13.1 dup (Prader-Willi region dup): M = 26, F = 21; 16p11.2 dup: M = 29,
F = 16; 16p13.11 dup: M = 25, F = 26; 22q11.2 del (DiGeorge Syndrome): M = 35, F = 30; Smith Magenis Syndrome (SMS): M = 10, F = 13; 22q13
del: M = 11, F = 34
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CNVs within individuals with ID/DD but not with aut-
ism. Among individuals with ID/DD (Fig. 2c, Additional
file 1: Table S8), trends toward a higher frequency of co-
morbid features were observed in girls or boys for cer-
tain CNVs. These differences were larger for CNVs
associated with variable expressivity, and the smallest dif-
ferences were seen for CNVs associated with syndromes
such as DiGeorge syndrome, Phelan-McDermid syn-
drome, and Smith-Magenis syndrome.
Sex ratio of individuals with autism or ID/DD
We sought to assess the male:female ratio of individuals
with autism and ID/DD who were also showing specific co-
morbidities (Fig. 3). First, the sex ratio of autism withoutcomorbidities was 4.2:1, similar to recent epidemiological
reports [3]. Interestingly, we found that the sex ratios of
individuals with autism or ID/DD varied based on specific
comorbid clinical features. In fact, while an 8:1 sex ratio
existed among individuals with autism also manifesting
psychiatric features, a 3.2:1 sex ratio was observed among
autistic individuals manifesting ID/DD, and a 2.5:1 sex ra-
tio for those also manifesting epilepsy (Additional file 1:
Table S9). Similarly, when compared to the 1.6:1 ratio for
ID/DD without comorbidities, the sex ratio increased to
3.2:1 in individuals with autism comorbidity and de-
creased to 1.1:1 in individuals manifesting ID/DD with
features of epilepsy.
Sex ratio also varied when the number of boys and girls












































































































































































































Male to female ratio in ID/DDA B
Male
Female
Fig. 3 Sex ratio for specific comorbidities in individuals with autism and ID/DD. The male:female ratio of individuals manifesting (a) autism, and
(b) ID/DD, with specific comorbidities is shown. For this analysis, the other congenital malformations category also included growth abnormalities,
kidney malformations, cardiac malformations, and dysmorphic features. Sample sizes (n) for each combination of comorbid features (with autism or
ID/DD) is provided in Additional file 1: Table S9
Polyak et al. Genome Medicine  (2015) 7:94 Page 6 of 11file 1: Table S10). For example, among individuals with
autism, a male:female ratio of 3:1 was observed for 1q21.1
duplication, 2.3:1 for 15q11.2q13.1 duplication, 1.6:1 for
15q11.2 deletion, and 1.3:1 for 16p11.2 deletion. Further,
among individuals with ID/DD, a male:female ratio of
2.6:1 was observed for 22q11.2 duplication, 1.6:1 for
16p11.2 deletion, and 0.3:1 for 22q13 deletion. While bias
in clinical ascertainment can contribute to these observa-
tions, our results suggest that the spectrum of autism or
ID/DD in boys and girls is contingent upon the presence
































































































































Fig. 4 Sex ratio for individuals with autism or ID/DD also carrying specific C
and duplications also manifesting features of (a) autism and (b) ID/DD. SamCNV burden among boys and girls with autism, ID/DD,
and comorbid phenotypes
We explored a sex bias for rare CNV burden among
individuals with autism or ID/DD with and without co-
morbid phenotypes (Fig. 5, Additional file 1: Table S11).
Overall, when all comorbidities were considered separately
or in aggregate, girls showed a significantly increased large
CNV burden compared to boys for a primary diagnosis of
autism or ID/DD (Fig. 5a-c). Further, when individuals
manifesting autism or ID/DD without any comorbidities
were compared, girls showed a higher burden for large



































































































Male to female ratio of ID/DD within CNVs
Male
Female
NVs. The male:female ratio of individuals carrying specific deletions
ple sizes (n) for each CNV is provided in Additional file 1: Table S10
AC
Autism no comorbidities male
Autism no comorbidities female
Autism+comorbidities male
Autism+comorbidities female
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ID/DD no comorbidities female
ID/DD+comorbidities male
ID/DD+comorbidities female











































Fig. 5 CNV burden in autism and ID/DD cohorts. Population
frequency of the largest CNV in individuals with autism, ID/DD,
epilepsy, and/or other comorbidities is shown. Using the rare CNV
cohort, survivor functions were generated for the population
frequency carrying a CNV larger than a given size. CNV burden plots
are shown for: (a) boys (dashed lines) and girls (solid lines) with
autism with or without any comorbidities; (b) boys (dashed lines)
and girls (solid lines) with ID/DD with or without any comorbidities;
(c) boys (dashed lines) and girls (solid lines) with autism with ID, autism
with epilepsy, and ID with epilepsy are shown. Full statistical analysis
including sample sizes (n) is provided in Additional file 1: Table S11
Polyak et al. Genome Medicine  (2015) 7:94 Page 7 of 11difference in CNV burden between boys and girls seemed
to decrease in magnitude when individuals ascertained
with ID/DD were considered (Fig. 5b). These observa-
tions were also replicated by a reanalysis of previously
published CNV data from independently ascertained
autism cohorts from the Simons Simplex Collection
[19] and the CHARGE study [42] (Additional file 1:
Figure S3A, B, Table S12). A significantly higher CNV
burden was also observed for girls compared to boys(Mann Whitney test, one-tailed P = 0.009) manifesting
autism with or without ID/DD when total base pairs of de
novo CNV per person in these independently ascertained
cohorts were considered (Additional file 1: Figure S3C).
Assessment of family history of neurodevelopmental
phenotypes in boys and girls
From the 386 individuals with neurodevelopmental phe-
notypes for whom family history information was avail-
able, a frequency matrix of family history and clinical
indications grouped into 12 phenotypic categories was
generated. Frequencies were calculated from the number
of individuals with a specific indication and a specific
family history as the numerator and the total number of
individuals with that indication with any family history
as the denominator (Fig. 6, Additional file 1: Figure S4).
A family history of ID/DD tended to exist consistently in
all clinical indications. Although no sex difference was
observed when all family histories were considered in
aggregate (P = 0.48), significant differences existed within
specific family history phenotypes. Of all affected
individuals with a family history of autism (Student’s t
test, one-tailed P = 0.01) and specific learning disability
(Student’s t test, one-tailed P = 0.03), we found a higher
frequency of boys compared to girls. In contrast, we
observed a higher frequency of girls than boys when in-
dividuals with a family history of growth abnormalities
were considered (Student’s t test, one-tailed P = 0.02).
We were then able to categorize the 12 phenotypes into
two broad groups of ID/DD/MCA disorders and neuro-
psychiatric/behavioral disorders based on the age-
specific prevalence within the cohort (Additional file 1:
Figure S1). Among individuals with a family history of a
broader ID/DD/MCA disorders, no differences in the
frequency of boys compared to girls with indications of ID/
DD/MCA were observed (Mann Whitney test, P = 0.13).
However, we observed a higher frequency of boys manifest-
ing neuropsychiatric/behavioral disorders compared to girls
when all individuals with a family history of neuropsychi-
atric/behavioral disorders were evaluated (Mann Whitney
test, P = 0.03).
Discussion
We sought to dissect the various factors affecting sex bias
in autism and intellectual disability disorders. This study
is the first to connect clinical data including diagnostic
indications and family history with genomic data on
CNVs. Ideally, standardized diagnostic measures and deep
phenotyping would be useful in the ascertainment of indi-
viduals with neurodevelopmental disorders. However,
such measures are not always available, especially within a
large clinically heterogeneous population such as the Sig-
nature Genomics cohort. Instead, we provide a realistic as-
sessment of how the documented sex bias extends to
Males Females























































































































































































































































































































Fig. 6 Family history among individuals with neurodevelopmental phenotypes. Matrices were generated showing percentage of individuals with
a clinical indication and a specific family history among all individuals with that specific indication and any family history: boys (left, n = 236) and
girls (right, n = 150). Family history is represented on the Y-axis, and the clinical indication of the proband is on the X-axis. The frequency of family
history is depicted as a range of colors. A graphical description of the comparisons made is provided in Additional file 1: Figure S4
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velopmental disorders.
Several themes have emerged from our study. First,
the pervasive presence of comorbid features among
affected individuals was evident in our dataset, existing
in about half of individuals ascertained for autism or ID/
DD. We found that these comorbid features manifested
at different frequencies among boys and girls, with girls
as a whole more likely to have comorbidities. Within
specific categories of comorbidities, girls were more
likely than boys to manifest epilepsy with either autism
or ID/DD, consistent with previous reports [59–61].
These results suggest that while autism and ID/DD
disorders have a sex bias skewed towards boys, girls are
more likely to be diagnosed when they have additional
comorbid features. Interestingly, the sex difference in
the presence of comorbid features also varied across
individuals carrying specific CNVs. Differences were
most notable for individuals carrying CNVs associated
with variable phenotypes, with skewing toward either sex,
while in individuals with DiGeorge syndrome and Smith-
Magenis syndrome, where individuals typically manifest a
more fixed constellation of features, the frequency of
comorbid features was invariable among the sexes.
Second, the sex bias was not uniform across specific co-
morbid features and specific CNVs. In fact, while a 4.2:1
male:female ratio existed for autism without comorbidities,
a sex ratio shift toward girls (3.2:1) was observed for autism
with ID/DD and toward boys (8:1) for autism with psychi-
atric disorders. Our results are also supported by previousstudies that show a sex ratio of 6:1 [62] in high-functioning
individuals with autism and 2:1 within individuals with aut-
ism manifesting intellectual disability [63]. For those indi-
viduals ascertained for ID/DD, while there was a 1.6:1
male:female ratio for those with no comorbidities, we found
a 1.1:1 ratio for individuals also manifesting epilepsy. The
sex ratio of autism and ID/DD also corresponded to spe-
cific CNVs. For example, while individuals with autism car-
rying the 22q11.2 duplication had an 8:1 male:female ratio,
those carrying a 15q13.3 deletion or 16p11.2 deletion
showed a 1.3:1 sex ratio. Similarly, individuals with ID/DD
and carrying 22q11.2 duplication showed a male:female
ratio of 2.6:1, while those carrying DiGeorge syndrome
deletion or 15q11.2q13.1 (PWS region) duplication showed
a 1.2:1 sex ratio. Our analysis suggests that girls, while exhi-
biting more comorbidities than boys, are ascertained at a
closer frequency to their male counterparts when they are
more severely affected.
Third, the frequency of large CNVs, or CNV burden,
also corresponded to sex. Girls showed a higher CNV bur-
den than boys for autism alone or autism with comorbid
features. Interestingly, the CNV burden among girls with
autism with no comorbidities was similar to that in boys
manifesting autism with comorbidities (Fig. 5). This is
consistent with the recently reported female protective
model for neurodevelopmental disorders [6]. While a male
to female difference in CNV burden was observed among
individuals manifesting features of ID/DD without comor-
bidities and ID/DD with comorbidities, this difference in
CNV burden diminished in the latter cohort (Fig. 5c).
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den dissolves when applied to severely affected subsets.
Finally, the existence of positive family histories among
individuals ascertained for neurodevelopmental pheno-
types enabled us to further dissect the complex nature
of these disorders. Although there was a lack of statis-
tical power to derive significant associations for all phe-
notypes of varying severity analyzed for presenting
indications and family history, we found that affected
boys predominantly had neuropsychiatric family histor-
ies such as autism or specific learning disability, whereas
affected girls had developmental disorders in their family
histories such as growth abnormalities. A lack of statis-
tical power made any assessment of genetic liability
within this subset of individuals difficult. It is likely that
individuals with a family history of affected individuals
are more predisposed to a condition due to an increased
genetic liability within their family, and our results sug-
gest that sex also affects the likelihood of a child in these
families having a neurodevelopmental disorder [52].Conclusions
From our results, it is clear that the sex bias is not limited
to the initial diagnosis of autism or ID/DD, but affects the
extent of heterogeneity. We observed variations in male:-
female ratios based on comorbid features, presence of
CNVs, and family history, but these ratios tend to dimin-
ish when applied to severely affected individuals. Future
studies of the phenotypic heterogeneity surrounding neu-
rodevelopmental disorders should take sex bias into
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